What is Sales and Marketing Strategy of ResMed Company?

Clinical education on sleep apnea risks (hypertension, AFib, road safety), CPAP tips, and mask-fit guides drive organic search and referrals; localized clinic pages increase referral conversion.

Search and social campaigns target high-intent queries (snoring, daytime sleepiness) and caregiver segments; retargeting supports resupply and mask upgrades timed to payer open enrollment.

myAir app and email/SMS journeys personalize onboarding; usage-triggered nudges lift 90-day compliance toward the industry threshold of ~70%, aiding payer reimbursement and DME margins.

Collaborations with respiratory therapists, sleep physicians, and patient advocates on YouTube, Instagram, and LinkedIn focus on setup, adherence, and reducing stigma to improve adoption.

Physician detailing, trade shows (ATS, SLEEP, Medtrade), and co-op campaigns with DMEs complement selective TV/radio in markets where an estimated ~80% of moderate-to-severe OSA remains undiagnosed globally.

AirView and myAir analytics enable segmentation and personalization; Brightree CRM/RCM automates resupply outreach, with A/B testing and API links to EHRs and payer portals in key markets.

Consistent top-tier share in masks and devices; industry awards for digital health and remote monitoring validate the position and support clinician preference tied to adherence outcomes and data access.

Key differentiators include the connected ecosystem, comfort-first mask portfolio, and enterprise software — all aligned to ResMed sales strategy and ResMed marketing strategy targeting providers, payers, and patients.

ResMed go-to-market strategy uses omnichannel distribution: direct sales to sleep clinics and hospitals, distributor partnerships for international reach, and DTC digital campaigns to support patient acquisition and retention.

Messaging highlights clinical outcomes and adherence metrics; ResMed leverages real-world data (device-derived adherence) to persuade clinicians and payers, supporting reimbursement and formulary inclusion.

Between 2021–2023 ResMed rapidly adjusted messaging and supply-chain communications during disruptions and accelerated promotion of COPD digital therapeutics and adherence tools as value-based care expanded.

Clinical-preference surveys and adherence analyses show higher setup-to-adherence conversion versus competitors; ResMed emphasizes these metrics in B2B sales pitches and payer negotiations to demonstrate ROI.

Objective: manage demand surge after a competitor recall with transparent supply updates, clinical guidance and prioritized allocations. Channels: provider portals, email, earned media. Results: protected brand trust, expanded installed base and sustained share gains into 2024–2025.

Creative emphasis on patient outcomes and payer thresholds converted awareness into measurable adherence and resupply revenue, supporting contract negotiations and payer compliance requirements.

Automated in-app coaching and segmented CRM journeys delivered individualized touchpoints, driving 90-day compliance lifts and higher lifetime value per patient.

Tightly integrating with Brightree and MatrixCare reduced days-to-setup, increased clean-claim rates and enabled scalable cross-sell into hospital and clinic channels.

Campaigns reported higher HST-to-therapy conversion, payer-compliant adherence levels, and improved resupply revenue; internal metrics cite double-digit adherence gains and reduced cost-per-diagnosis in targeted regions.

See detailed competitive analysis and market positioning in the article Competitors Landscape of ResMed for comparisons versus Philips Respironics and other peers.